Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The Role of Sumoylation in Senescence.

Scurr LL, Haferkamp S, Rizos H.

Adv Exp Med Biol. 2017;963:215-226. doi: 10.1007/978-3-319-50044-7_13. Review.

PMID:
28197915
2.

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

Todd JR, Scurr LL, Becker TM, Kefford RF, Rizos H.

Oncogene. 2014 Jan 9;33(2):236-45. doi: 10.1038/onc.2012.562. Epub 2012 Dec 17.

PMID:
23246970
3.

Absence of distinguishing senescence traits in human melanocytic nevi.

Tran SL, Haferkamp S, Scurr LL, Gowrishankar K, Becker TM, Desilva C, Thompson JF, Scolyer RA, Kefford RF, Rizos H.

J Invest Dermatol. 2012 Sep;132(9):2226-34. doi: 10.1038/jid.2012.126. Epub 2012 Apr 19.

4.

Selective loss of wild-type p16(INK4a) expression in human nevi.

Scurr LL, McKenzie HA, Becker TM, Irvine M, Lai K, Mann GJ, Scolyer RA, Kefford RF, Rizos H.

J Invest Dermatol. 2011 Nov;131(11):2329-32. doi: 10.1038/jid.2011.197. Epub 2011 Jul 7. No abstract available.

5.

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.

Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P.

BMC Cancer. 2011 May 27;11:203. doi: 10.1186/1471-2407-11-203.

6.

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.

Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021.

7.

Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes.

Becker TM, Philipsz S, Scurr LL, Fung C, Haferkamp S, Kefford RF, Rizos H.

J Invest Dermatol. 2010 Aug;130(8):2144-7. doi: 10.1038/jid.2010.117. Epub 2010 May 6. No abstract available.

8.

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF, Rizos H.

Aging (Albany NY). 2009 May 16;1(6):542-56.

9.

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

Haferkamp S, Scurr LL, Becker TM, Frausto M, Kefford RF, Rizos H.

J Invest Dermatol. 2009 Aug;129(8):1983-91. doi: 10.1038/jid.2009.5. Epub 2009 Feb 12.

10.

Wild type and melanoma-associated mutant p16(IN4a) proteins do not oligomerize in vivo.

McKenzie H, Becker TM, Scurr LL, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2009 Feb;22(1):131-3. doi: 10.1111/j.1755-148X.2008.00530.x. No abstract available.

PMID:
19154236
11.

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.

Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, Diefenbach E, Scolyer RA, Reisman DN, Mann GJ, Kefford RF, Rizos H.

Mol Cancer. 2009 Jan 16;8:4. doi: 10.1186/1476-4598-8-4.

12.

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.

Clin Cancer Res. 2008 Nov 1;14(21):6924-32. doi: 10.1158/1078-0432.CCR-07-5189.

13.

p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, Dunleavey R, Mann GJ, Kefford RF, Rizos H.

Neoplasia. 2008 Nov;10(11):1231-9.

14.

p16INK4a-induced senescence is disabled by melanoma-associated mutations.

Haferkamp S, Becker TM, Scurr LL, Kefford RF, Rizos H.

Aging Cell. 2008 Oct;7(5):733-45.

15.

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

Rizos H, Scurr LL, Irvine M, Alling NJ, Kefford RF.

Cell Cycle. 2007 Jul 15;6(14):1741-7. Epub 2007 May 10.

PMID:
17630509
16.

Physical and functional interaction of the p14ARF tumor suppressor with ribosomes.

Rizos H, McKenzie HA, Ayub AL, Woodruff S, Becker TM, Scurr LL, Stahl J, Kefford RF.

J Biol Chem. 2006 Dec 8;281(49):38080-8. Epub 2006 Oct 11.

17.

Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity.

Arnett-Mansfield RL, Graham JD, Hanson AR, Mote PA, Gompel A, Scurr LL, Gava N, de Fazio A, Clarke CL.

Mol Endocrinol. 2007 Jan;21(1):14-29. Epub 2006 Oct 4.

PMID:
17021053
18.

Retinal light damage: structural and functional effects of the antioxidant glutathione peroxidase-1.

Gosbell AD, Stefanovic N, Scurr LL, Pete J, Kola I, Favilla I, de Haan JB.

Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2613-22.

PMID:
16723478
19.

Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy.

de Haan JB, Stefanovic N, Nikolic-Paterson D, Scurr LL, Croft KD, Mori TA, Hertzog P, Kola I, Atkins RC, Tesch GH.

Am J Physiol Renal Physiol. 2005 Sep;289(3):F544-51. Epub 2005 Apr 12.

20.

Inhibition of antigen and calcium ionophore induced secretion from RBL-2H3 cells by phosphatase inhibitors.

Ludowyke RI, Warton K, Scurr LL.

Cell Biol Int. 1998 Nov;22(11-12):855-65.

PMID:
10873297
21.

Induction of interleukin-4 and interleukin-5 expression in mast cells is inhibited by glucocorticoids.

Sewell WA, Scurr LL, Orphanides H, Kinder S, Ludowyke RI.

Clin Diagn Lab Immunol. 1998 Jan;5(1):18-23.

22.
23.

Supplemental Content

Loading ...
Support Center